[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100389155":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":48,"collaborators":7,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":7,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Antiplatelet Drug","single or dual antiplatelets, triple antithrombotic therapy",[14],"anticoagulant Drug",[16],{"name":17,"affiliation":5,"role":18},"Elizaveta Panchenko, PhD","PRINCIPAL_INVESTIGATOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Andrey Komarov, PhD","CONTACT","+79161813257","andrkomarov@mail.ru",[26],{"facility":5,"status":27,"city":28,"state":7,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Moscow","121552","Russia","RU",{"type":33,"coordinates":34},"Point",[35,36],37.61781,55.75204,{"lat":36,"lon":35},[39,40,43,44,46],{"name":17,"role":18,"phone":7,"phoneExt":7,"email":7},{"name":41,"role":42,"phone":7,"phoneExt":7,"email":7},"Olga Shakhmatova, PhD","SUB_INVESTIGATOR",{"name":21,"role":42,"phone":7,"phoneExt":7,"email":7},{"name":45,"role":42,"phone":7,"phoneExt":7,"email":7},"Elena Yarovaya, PhD",{"name":47,"role":42,"phone":7,"phoneExt":7,"email":7},"Alla Shuleshova, PhD",{"type":49,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100389155","registry-of-long-term-antithrombotic-therapy-1-100389155",false,"NCT04347200","REGistry of Long-term AnTithrombotic TherApy-1","Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes","REGATTA-1","Inclusion Criteria:\n\n* coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging\n\nExclusion Criteria:\n\n* Subjects who are unwilling or unable to provide informed consent.\n* Acute coronary syndrome within 12 months before inclusion\n* Severe chronic heart failure (NYHA IV)\n* Stroke within 6 months before inclusion\n* Severe liver or muscle disease\n* Severe kidney disease \u002F renal failure with creatinine \\> 3 mg\u002Fdl\n* Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -","ALL","18 Years",{"count":61,"type":62},2000,"ESTIMATED","5 Years","OBSERVATIONAL","To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes",[67,68],"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))","Peripheral Artery Disease",[70],"Coronary Artery Disease, Peripheral Artery Disease","2026-04-27",{"date":73,"type":74},"2026-05-01","ACTUAL",{"date":76,"type":74},"2015-01-15",{"date":78,"type":62},"2026-12-31",{"name":5,"class":6},1]